Aleksey N. Krylov
Interim Chief Financial Officer
Sellas Life Sciences Group
Mr. Krylov has served as SELLAS’ Interim Chief Financial Officer since October 2017. Prior to joining SELLAS, Mr. Krylov acted as a consultant to CHR Capital Inc., where he functioned as a vice president and investment analyst with a focus on mergers and acquisitions, capital raising, private equity investment and restructuring transactions, among other items, from March 2012 through October 2017. Before that, Mr. Krylov provided consulting services to a number of additional companies through Ftera Advisors, LLC, or Ftera, a financial consulting firm that works with early-stage and small-cap companies in various industries including biotechnology. Mr. Krylov founded his consulting business in 2009, formed Ftera in 2012 and has been the managing director of Ftera since that time. Mr. Krylov began his career with SG Cowen’s equity capital markets group as an investment banking analyst. Mr. Krylov holds an M.B.A. from Columbia Business School and a B.S. in Business Administration from Babson College. He is a CFA charterholder.
Pharmaceutical Analysis and Quality Assurance Industrial Pharmacy Clinical Pharmacy Pharmaceutical Administration Medicinal Chemistry Drug Discovery and Development